40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
View analysts' price targets and recommendations, and compare them with competitors.
$52.00
Lower upside than CVE's upside of 85.41%.
Buy
Better than CVE's analyst recommendation of Hold.
Analyze analyst forecasts for the company and compare them with competitors.
5.41B
The estimated revenue has decreased from the previous period.
558.96M
The estimated EBITDA has increased from the previous period.
2.40
The estimated EPS has increased from the previous period.
326.46M
The estimated net income has increased from the previous period.
864.80M
The estimated EBIT has increased from the previous period.
347.17M
The estimated SG&A expenses have decreased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
8.66B
Revenue has increased from the previous period.
42.24%
Revenue growth rate has increased from the previous period.
2.79B
EBITDA has increased from the previous period.
32.24%
EBITDA margin has increased from the previous period.
1.58B
EBIT has increased from the previous period.
18.24%
EBIT margin has increased from the previous period.
1.21B
Depreciation has decreased from the previous period.
195.00M
Total cash has increased from the previous period.
2.25%
Cash percentage has increased from the previous period.
1.30B
Receivables have increased from the previous period.
14.97%
Receivables percentage has increased from the previous period.
9.00M
Inventories have decreased from the previous period.
0.10%
Inventory percentage has decreased from the previous period.
328.00M
Accounts payable has increased from the previous period.
3.79%
Payables percentage has decreased from the previous period.
-1.52B
Capital expenditure has decreased from the previous period.
-17.54%
CapEx percentage has decreased from the previous period.
12.25%
WACC is unchanged from the previous period.
16.87%
Cost of equity is unchanged from the previous period.
5.31%
Cost of debt is unchanged from the previous period.
2.64
Beta is unchanged from the previous period.
263.90M
Diluted shares outstanding is unchanged from the previous period.
6.68B
Total debt is unchanged from the previous period.
10.03B
Total equity is unchanged from the previous period.
16.71B
Total capital is unchanged from the previous period.
39.98%
Debt weighting is unchanged from the previous period.
60.02%
Equity weighting is unchanged from the previous period.
1.80B
EBIAT has increased from the previous period.
1.10B
UFCF has increased from the previous period.
0.50%
Long-term growth rate is unchanged from the previous period.
-12.22B
Terminal value is unchanged from the previous period.
-10.85B
Enterprise value is unchanged from the previous period.
6.68B
Net debt is unchanged from the previous period.
-17.53B
Equity value is unchanged from the previous period.
-66.42
Equity value per share is unchanged from the previous period.
